HCAT vs. IPSC, PHAR, AVIR, COLL, CARA, ANAB, EHAB, IMAB, BVS, and RAPT
Should you be buying Health Catalyst stock or one of its competitors? The main competitors of Health Catalyst include Century Therapeutics (IPSC), Pharming Group (PHAR), Atea Pharmaceuticals (AVIR), Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), AnaptysBio (ANAB), Enhabit (EHAB), I-Mab (IMAB), Bioventus (BVS), and RAPT Therapeutics (RAPT). These companies are all part of the "medical" sector.
Health Catalyst vs.
Century Therapeutics (NASDAQ:IPSC) and Health Catalyst (NASDAQ:HCAT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.
In the previous week, Health Catalyst had 1 more articles in the media than Century Therapeutics. MarketBeat recorded 12 mentions for Health Catalyst and 11 mentions for Century Therapeutics. Health Catalyst's average media sentiment score of 0.61 beat Century Therapeutics' score of 0.55 indicating that Health Catalyst is being referred to more favorably in the news media.
57.5% of Century Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Health Catalyst shares are held by institutional investors. 10.3% of Century Therapeutics shares are held by company insiders. Comparatively, 1.5% of Health Catalyst shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Century Therapeutics presently has a consensus price target of $27.00, indicating a potential upside of 110.61%. Health Catalyst has a consensus price target of $26.69, indicating a potential upside of 97.14%. Given Century Therapeutics' higher possible upside, analysts clearly believe Century Therapeutics is more favorable than Health Catalyst.
Century Therapeutics has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Health Catalyst has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.
Century Therapeutics has higher earnings, but lower revenue than Health Catalyst. Century Therapeutics is trading at a lower price-to-earnings ratio than Health Catalyst, indicating that it is currently the more affordable of the two stocks.
Century Therapeutics has a net margin of 0.00% compared to Health Catalyst's net margin of -54.64%. Health Catalyst's return on equity of -18.31% beat Century Therapeutics' return on equity.
Health Catalyst received 114 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 71.10% of users gave Health Catalyst an outperform vote while only 45.00% of users gave Century Therapeutics an outperform vote.
Summary
Health Catalyst beats Century Therapeutics on 13 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HCAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Health Catalyst Competitors List